Cost–Utility of First-Line Actinic Keratosis Treatments in Finland

Overview of attention for article published in Advances in Therapy, May 2015

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (71st percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

policy: 1 policy source

twitter: 2 X users

Readers on

mendeley: 50 Mendeley

Summary Policy documents X

So far, Altmetric has seen 1 policy document that references this research output.

Imiquimod for the Treatment of Actinic Keratosis: A Review of Clinical and Cost-Effectiveness

Cited by Canadian Agency for Drugs and Technologies in Health on 15 Sep 2017

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.